Symbols / ESLAW Stock $0.12 +21.20% Estrella Immunopharma, Inc.

Healthcare • Biotechnology • United States • NCM
ESLAW (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Cheng Liu Ph.D.
Exch · Country NCM · United States
Market Cap —
Enterprise Value —
Income -11.11M
Sales —
FCF (ttm) 2.81M
Book/sh -2.89
Cash/sh 0.07
Employees —
Insider 10d —
IPO —
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E —
PEG —
P/S —
P/B -0.04
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 0.25
Current Ratio 0.28
Debt/Eq —
LT Debt/Eq —
EPS (ttm) —
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -174.75%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand —
Shs Float 9.10M
Insider Own —
Instit Own —
Short Float —
Short Ratio —
Short Interest —
52W High 0.12
vs 52W High 0.00%
52W Low 0.12
vs 52W Low 0.00%
Beta -0.09
Impl. Vol. —
Rel Volume —
Avg Volume —
Volume 500.00
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.10
Price $0.12
Change 21.20%
About

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.12
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$0.12
Low
—
High
—
Mean
—
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-06-30 2023-06-30 2022-06-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
13.06
+78.69%
7.31
-34.23%
11.11
+559.47%
1.69
Research And Development
10.25
+149.42%
4.11
-60.68%
10.45
+652.37%
1.39
Selling General And Administration
2.81
-12.09%
3.20
+382.69%
0.66
+123.86%
0.30
General And Administrative Expense
2.81
-12.09%
3.20
+382.69%
0.66
+123.86%
0.30
Other Gand A
2.81
-12.09%
3.20
+382.69%
0.66
+123.86%
0.30
Total Expenses
13.06
+78.69%
7.31
-34.23%
11.11
+559.47%
1.69
Operating Income
-13.06
-78.69%
-7.31
+34.23%
-11.11
-559.47%
-1.69
Total Operating Income As Reported
-13.06
-78.69%
-7.31
+34.23%
-11.11
-559.47%
-1.69
EBITDA
-13.06
-78.69%
-7.31
+34.23%
-11.11
-559.47%
-1.69
Normalized EBITDA
-13.06
-78.69%
-7.31
+34.23%
-11.11
-559.47%
-1.69
EBIT
-13.06
-78.69%
-7.31
+34.23%
-11.11
-559.47%
-1.69
Net Income
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Pretax Income
-13.06
-78.69%
-7.31
+34.23%
-11.11
-559.47%
-1.69
Tax Provision
0.00
-48.43%
0.00
0.00
0.00
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Net Income From Continuing Operation Net Minority Interest
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Net Income From Continuing And Discontinued Operation
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Net Income Continuous Operations
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Normalized Income
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Net Income Common Stockholders
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Diluted NI Availto Com Stockholders
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Line Item Trend 2025-12-31 2024-06-30
Total Assets
3.18
-28.67%
4.45
Current Assets
1.68
-62.35%
4.45
Cash Cash Equivalents And Short Term Investments
1.38
-66.77%
4.17
Cash And Cash Equivalents
1.38
-66.77%
4.17
Cash Financial
—
—
Receivables
0.29
+1.35%
0.29
Other Receivables
0.29
+1.35%
0.29
Prepaid Assets
—
—
Total Non Current Assets
1.50
0.00
Non Current Deferred Assets
—
0.00
Non Current Prepaid Assets
1.50
0.00
Total Liabilities Net Minority Interest
13.54
+7394.72%
0.18
Current Liabilities
13.54
+7394.72%
0.18
Payables And Accrued Expenses
13.19
+7197.43%
0.18
Payables
0.63
+1037.69%
0.06
Accounts Payable
0.55
0.00
Other Payable
0.06
+16470.89%
0.00
Current Accrued Expenses
12.56
+9925.55%
0.13
Total Tax Payable
0.02
-65.98%
0.06
Income Tax Payable
0.00
-100.00%
0.04
Other Current Liabilities
0.36
—
Total Non Current Liabilities Net Minority Interest
0.00
0.00
Other Non Current Liabilities
—
—
Preferred Securities Outside Stock Equity
0.00
0.00
Stockholders Equity
-10.37
-342.57%
4.27
Common Stock Equity
-10.37
-342.57%
4.27
Capital Stock
0.00
+5.14%
0.00
Common Stock
0.00
+5.14%
0.00
Preferred Stock
—
0.00
Share Issued
38.49
+5.12%
36.61
Ordinary Shares Number
37.97
+4.63%
36.29
Treasury Shares Number
0.52
+60.13%
0.32
Additional Paid In Capital
27.22
+12.83%
24.12
Retained Earnings
-36.99
-89.69%
-19.50
Treasury Stock
0.60
+68.82%
0.35
Total Equity Gross Minority Interest
-10.37
-342.57%
4.27
Total Capitalization
-10.37
-342.57%
4.27
Working Capital
-11.87
-377.67%
4.27
Invested Capital
-10.37
-342.57%
4.27
Net Tangible Assets
-10.37
-342.57%
4.27
Tangible Book Value
-10.37
-342.57%
4.27
Notes Receivable
—
0.00
Preferred Stock Equity
—
—
Line Item Trend 2025-12-31 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-1.79
+88.89%
-16.07
-1102.61%
-1.34
+7.34%
-1.44
Cash Flow From Continuing Operating Activities
-1.79
+88.89%
-16.07
-1102.61%
-1.34
+7.34%
-1.44
Net Income From Continuing Operations
-13.06
-78.67%
-7.31
+34.21%
-11.11
-559.47%
-1.69
Stock Based Compensation
0.62
-48.19%
1.19
+191.67%
0.41
+215.15%
0.13
Operating Gains Losses
0.04
—
—
—
Gain Loss On Investment Securities
0.04
—
—
—
Change In Working Capital
10.62
+206.73%
-9.95
-206.22%
9.37
+8165.20%
0.11
Change In Prepaid Assets
0.43
+387.47%
-0.15
-118.00%
0.83
+200.00%
-0.83
Change In Payables And Accrued Expense
10.19
+203.96%
-9.80
-214.83%
8.54
+801.61%
0.95
Change In Accrued Expense
9.61
+53470.37%
-0.02
-181.82%
0.02
-97.67%
0.95
Change In Payable
0.58
+105.96%
-9.78
-214.92%
8.51
—
Change In Account Payable
0.55
+105.90%
-9.33
-211.27%
8.39
—
Investing Cash Flow
—
4.96
+1916.65%
-0.27
0.00
Cash Flow From Continuing Investing Activities
—
4.96
+1916.65%
-0.27
—
Net Other Investing Changes
—
4.96
+1916.65%
-0.27
—
Financing Cash Flow
2.25
-82.39%
12.79
0.00
-100.00%
5.53
Cash Flow From Continuing Financing Activities
2.25
-82.39%
12.79
0.00
-100.00%
5.53
Net Issuance Payments Of Debt
—
0.00
0.00
—
Issuance Of Debt
—
0.30
0.00
—
Repayment Of Debt
—
-0.30
0.00
—
Long Term Debt Issuance
—
0.30
0.00
—
Long Term Debt Payments
—
-0.30
0.00
—
Net Long Term Debt Issuance
—
0.00
0.00
—
Short Term Debt Issuance
—
0.30
—
—
Short Term Debt Payments
—
-0.30
—
—
Net Short Term Debt Issuance
—
0.00
—
—
Net Common Stock Issuance
2.37
+768.81%
-0.35
0.00
—
Common Stock Payments
-0.03
+91.69%
-0.35
0.00
—
Repurchase Of Capital Stock
-0.03
+91.69%
-0.35
0.00
—
Proceeds From Stock Option Exercised
—
—
—
0.01
Net Other Financing Charges
-0.12
-102.85%
4.13
—
—
Changes In Cash
0.47
-72.28%
1.69
+204.79%
-1.61
—
Beginning Cash Position
0.92
-63.01%
2.48
-39.36%
4.09
0.00
End Cash Position
1.38
-66.77%
4.17
+68.02%
2.48
-39.36%
4.09
Free Cash Flow
-1.79
+88.89%
-16.07
-1102.61%
-1.34
+7.34%
-1.44
Interest Paid Supplemental Data
0.00
-100.00%
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
-42.94%
0.00
0.00
0.00
Change In Income Tax Payable
-0.00
-2931.88%
-0.00
-104.31%
0.00
+191.70%
0.00
Change In Tax Payable
-0.00
-2931.88%
-0.00
-104.31%
0.00
+191.70%
0.00
Common Stock Issuance
2.40
0.00
—
—
Issuance Of Capital Stock
2.40
-73.39%
9.02
0.00
-100.00%
5.00
Net Preferred Stock Issuance
—
9.02
0.00
-100.00%
5.00
Preferred Stock Issuance
—
9.02
0.00
-100.00%
5.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category